Literature DB >> 23912246

AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers.

Wenbin Huang1, Li Yang, Song Liang, Dongxiao Liu, Xi Chen, Zhuo Ma, Sulan Zhai, Ping Li, Xuerong Wang.   

Abstract

BACKGROUND: Perifosine, an alkylphospholipid, is an Akt inhibitor which inhibits the growth of diverse cancer cells. We have reported its inhibitory effects on the growth of gastric cancer cells recently, but its molecular mechanisms are still largely unknown. AIMS: The purpose of this study was to investigate the effect and regulatory mechanism of perifosine in gastric cancer.
METHODS: Cell viability was determined by sulforhodamine B assay after transiently transfected with AEG-1 specific siRNAs. qRT-PCR and western blot assay were used to determine the mRNA expression and proteins levels of cell signaling molecules examined. Immunohistochemistry was used to detect the AEG-1 expression in 87 gastric carcinomas, 60 dysplasia, and 47 normal gastric mucosa.
RESULTS: Perifosine decreased AEG-1 gene expression along with inhibition of Akt/GSK3β/C-MYC signaling pathway. Knockdown of AEG-1 using siRNA led to significant down-regulation of cyclin D1 expression at both mRNA level and protein level, and inhibited the growth of gastric cancer cells. AEG-1 expression was elevated in gastric dysplasia and cancer tissues compared to normal gastric mucosa (P < 0.01). AEG-1 over-expression correlated with diffuse type of gastric cancer and advanced tumor stages.
CONCLUSIONS: Perifosine inhibits the growth of gastric cancer cells possibly through inhibition of the Akt/GSK3β/C-MYC signaling pathway-mediated down-regulation of AEG-1 that subsequently down-regulated cyclin D1. AEG-1 may play an important role in the carcinogenesis and progression of gastric cancer and could be a therapeutic target of perifosine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912246     DOI: 10.1007/s10620-013-2735-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

2.  Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways.

Authors:  Maria Nyåkern; Alessandra Cappellini; Irina Mantovani; Alberto M Martelli
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

3.  Astrocyte-elevated gene-1 overexpression is associated with poor prognosis in gastric cancer.

Authors:  Xu Jian-bo; Wu Hui; He Yu-long; Zhang Chang-hua; Zhang Long-juan; Cai Shi-rong; Zhan Wen-hua
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

4.  Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.

Authors:  Song Liang; Renhua Guo; Zhihong Zhang; Dongxiao Liu; Hao Xu; Zekuan Xu; Xuerong Wang; Li Yang
Journal:  Oncol Rep       Date:  2013-04-09       Impact factor: 3.906

5.  Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.

Authors:  Xuerong Wang; Ping Yue; Young Ae Kim; Haian Fu; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

6.  Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling.

Authors:  S-G Lee; Z-Z Su; L Emdad; D Sarkar; T F Franke; P B Fisher
Journal:  Oncogene       Date:  2007-08-20       Impact factor: 9.867

7.  Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.

Authors:  Pier Luigi Tazzari; Giovanna Tabellini; Francesca Ricci; Veronica Papa; Roberta Bortul; Francesca Chiarini; Camilla Evangelisti; Giovanni Martinelli; Andrea Bontadini; Lucio Cocco; James A McCubrey; Alberto M Martelli
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

8.  The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.

Authors:  Anna Dubrovska; Sungeun Kim; Richard J Salamone; John R Walker; Sauveur-Michel Maira; Carlos García-Echeverría; Peter G Schultz; Venkateshwar A Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-30       Impact factor: 11.205

9.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Authors:  Sudhir B Kondapaka; Sheo S Singh; Girija P Dasmahapatra; Edward A Sausville; Krishnendu K Roy
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

10.  The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.

Authors:  Heath A Elrod; Yi-Dan Lin; Ping Yue; Xuerong Wang; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cancer Ther       Date:  2007-06-29       Impact factor: 6.261

View more
  16 in total

1.  Depletion of astrocyte elevated gene-1 suppresses tumorigenesis through inhibition of Akt activity in bladder cancer cells.

Authors:  Lianhua Zhang; Guoliang Yang; Haige Chen; Yiran Huang; Wei Xue; Juanjie Bo
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  High expression of astrocyte elevated gene-1 is associated with clinical staging, metastasis, and unfavorable prognosis in gastric carcinoma.

Authors:  Liangpeng Dong; Shuang Qin; Yan Li; Lunde Zhao; Shuping Dong; Ying Wang; Caifeng Zhang; Shilin Han
Journal:  Tumour Biol       Date:  2014-11-19

3.  Metadherin in prostate, bladder, and kidney cancer: A systematic review.

Authors:  Zhao Wang; Yong-Bao Wei; Yun-Liang Gao; Bin Yan; Jin-Rui Yang; Qiong Guo
Journal:  Mol Clin Oncol       Date:  2014-08-18

4.  MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1.

Authors:  Xinsheng Shen; Yaqing Si; Zhugong Yang; Qun Wang; Jiaxiang Yuan; Xiefu Zhang
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

Review 5.  The role of MTDH/AEG-1 in the progression of cancer.

Authors:  Xue Shi; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.

Authors:  Zhongyuan Gao; Ting Yuan; Xiao Zhou; Ping Ni; Geng Sun; Ping Li; Zhixiang Cheng; Xuerong Wang
Journal:  Cancer Biol Ther       Date:  2018-02-06       Impact factor: 4.742

Review 7.  Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

Authors:  Shikha Satendra Singh; Wei Ney Yap; Frank Arfuso; Shreya Kar; Chao Wang; Wanpei Cai; Arunasalam M Dharmarajan; Gautam Sethi; Alan Prem Kumar
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

8.  Astrocyte elevated gene-1 is a novel biomarker of epithelial-mesenchymal transition and progression of hepatocellular carcinoma in two China regions.

Authors:  Jiasheng Zheng; Cong Li; Xia Wu; Yingzhuo Yang; Meijun Hao; Shoupeng Sheng; Yu Sun; Honghai Zhang; Jiang Long; Caixia Hu
Journal:  Tumour Biol       Date:  2013-10-18

9.  RNA interference-mediated knockdown of astrocyte elevated gene-1 inhibits growth, induces apoptosis, and increases the chemosensitivity to 5-fluorouracil in renal cancer Caki-1 cells.

Authors:  Peng Wang; Bo Yin; Liping Shan; Hui Zhang; Jun Cui; Mo Zhang; Yongsheng Song
Journal:  Mol Cells       Date:  2014-11-26       Impact factor: 5.034

10.  Astrocyte Elevated Gene-1 as a Novel Clinicopathological and Prognostic Biomarker for Gastrointestinal Cancers: A Meta-Analysis with 2999 Patients.

Authors:  Yihuan Luo; Xin Zhang; Zhong Tan; Peirong Wu; Xuelian Xiang; Yiwu Dang; Gang Chen
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.